Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib in combination with corticosteroids within its marketing authorisation for untreated chronic graft versus host disease.
Following on from information provided to NICE by the company in September 2020, the appraisal of Ibrutinib with corticosteroids for untreated chronic graft versus host disease was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3792
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Following on from information provided to NICE by the company in September 2020, the appraisal of Ibrutinib with corticosteroids for untreated chronic graft versus host disease was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 September 2020 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual